Italy· 045931021
FASENRA*1 penna preriempita SC 1 ml 30 mg/ml
A benralizumab product containing benralizumab, registered in Italy by ASTRAZENECA AB, on the national reimbursement list. The same ATC class is registered in 16 of our 19 countries.
Checked against the register on
Informational only — not a medical device.
Where it is registered
Benralizumab is registered in 16 of 19 countries.
Countries holding a registration under ATC R03DX10 (benralizumab), each read from that country’s own register.
- This record: Italy
- 10 of them publish a price we can compare per daily dose
Benralizumab · ATC R03DX10
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
- Active substance
- Benralizumab
- Manufacturer
- ASTRAZENECA AB
- Country
- Italy (IT)
- ATC code
- R03DX10
- ATC class
- Benralizumab
- Defined daily dose
- 0.54 mg, P
- Reimbursed
- Yes
- Last checked
- June 4, 2026
Packs & prices · 1
1 priced- aic045931021FASENRA*1 penna preriempita SC 1 ml 30 mg/mlEUR 3632.09
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Benralizumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandFasenraAstraZeneca AB
- United StatesFASENRAAstraZeneca Pharmaceuticals LP
- NorwayFasenraAstraZeneca AB (2)
- Japanベンラリズマブ（遺伝子組換え）アストラゼネカ
- SpainFASENRA 30 MG SOLUCION INYECTABLE EN JERINGA PRECARGADAAstrazeneca Ab
- FranceFASENRA 30 mg, solution injectable en seringue préremplieASTRAZENECA AB
- United KingdomFasenra 30mg/1ml solution for injection pre-filled pensAstraZeneca UK Ltd
- IcelandFasenraAstraZeneca AB
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Fasenra
- Liechtenstein · Fasenra
- Norway · Fasenra
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2d9992f1-b8df-4086-b994-ae6aa3179ad1 GET /v1/drugs/2d9992f1-b8df-4086-b994-ae6aa3179ad1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"price": 3632.09,
"source": "aifa",
"currency": "EUR",
"strength": "BENRALIZUMAB 30MG 1ML 1 UNITA' USO PARENTERALE",
"substance": "Benralizumab",
"equivalence_group": "KKX",
"transparency_flag": null
}See everything about benralizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.